BTK inhibitors are under close review for treating mantle cell lymphoma (MCL), a rare non‑Hodgkin lymphoma that impacts roughly four to six thousand Americans each year. Researchers at Tongji Hospital in Wuhan performed a systematic review that compares the three approved agents—first‑generation ibrutinib and second‑generation acalabrutinib and zanubrutinib—in both newly diagnosed and relapsed or refractory patients.
Because most comparative reviews of drugs within a class are funded by a sponsor of one competitor, the independence of this analysis is especially noteworthy; the authors explicitly reported no conflicts of interest or financial support from any drug manufacturer.
Scope and methods of the review
The team searched PubMed, Embase and Cochrane up to January 2025, locating seventy studies that met inclusion criteria. Those works comprised four randomized trials, three retrospective cohorts and sixty‑three single‑arm series. In total, the analysis covered 1,641 treatment‑naïve individuals and 1,791 patients whose disease had returned or persisted after prior therapy.
Endpoints extracted included complete response (CR), overall response (ORR), progression‑free survival (PFS), overall survival (OS) and adverse events. Random‑effects models were applied when heterogeneity (I²) exceeded fifty percent. Publication bias was examined with funnel plots and statistical tests such as Egger’s and Begg’s.
Efficacy in treatment‑naïve patients
Across the pooled data, CR rates were markedly higher in the treatment‑naïve cohort—seventy‑six point five percent, than in the relapsed or refractory group, which showed forty‑three point two percent. Corresponding ORRs reached ninety‑four point five percent and eighty‑one point two percent respectively.
The especially high CR rates reported for zanubrutinib in TP53‑mutant, treatment‑naïve patients (88 % in phase 2 cohorts) show its potential role in this genetically high‑risk subgroup, a point the authors highlighted when describing its frontline indication.
When broken down by drug, zanubrutinib achieved a ninety‑five point two percent CR rate in newly diagnosed patients, surpassing acalabrutinib at eighty‑nine point three percent and ibrutinib at sixty‑one point three percent. ORR followed a similar pattern, favoring the second‑generation agents.
These findings align with the 2025 National Full Cancer Network guideline, which promoted acalabrutinib (combined with bendamustine‑rituximab) to a preferred first‑line option after the ECHO trial demonstrated a thirty‑two percent reduction in risk of progression or death.
Future investigations may confirm whether newer BTK inhibitors become the default frontline choice, but the absence of direct head‑to‑head trials requires clinicians to weigh individual patient factors carefully.
Relapsed or refractory setting and combination approaches
In the relapsed or refractory group, monotherapy CR rates formed a modest gradient: acalabrutinib forty‑three point two percent, zanubrutinib thirty‑seven point eight percent and ibrutinib twenty‑seven point three percent.
Combination regimens improved outcomes. Adding a BTK inhibitor to CAR‑T cell therapy produced an eighty percent CR rate, while pairing a BTK inhibitor with anti‑CD20 antibodies and agents such as venetoclax, lenalidomide or proteasome inhibitors yielded a sixty‑eight point three percent CR rate. Both strategies outperformed BTK inhibitor monotherapy.
The CAR‑T data rest on a single trial of only twenty patients, so the impressive response must be taken with caution.
These results illustrate how chemotherapy‑free combinations can offset the historically poor prognosis of relapsed/refractory MCL, a theme the authors stress when interpreting the modest gains seen with BTK‑inhibitor plus small‑molecule backbones.
Safety profile and study limitations
Adverse‑event patterns differed among the drugs. Zanubrutinib showed the lowest neutropenia rates in treatment‑naïve patients and reduced thrombocytopenia in the relapsed setting. Cardiac events were most common with ibrutinib—seven point seven percent versus two point zero percent for acalabrutinib and zero point two percent for zanubrutinib.
Infections were reported more frequently with zanubrutinib in relapsed disease, sixty‑six point one percent versus thirty‑three point eight percent for ibrutinib and fifty‑three point seven percent for acalabrutinib. Hemorrhage rates were lowest for acalabrutinib.
The authors stress that most included studies were single‑arm, introducing selection bias and limiting generalizability. Moderate‑to‑high heterogeneity stemmed from varied patient demographics, TP53 mutation status, treatment lines and follow‑up lengths. Because many reports omitted survival data, a meta‑analysis of PFS and OS could not be performed.
They call for larger randomized controlled trials to confirm these indirect comparisons, noting that “These results provide a roadmap for optimizing MCL therapy.” but remains incomplete.
Given the emerging preference for second‑generation inhibitors and the promising signals from combination strategies, future research will likely focus on head‑to‑head trials and longer‑term safety monitoring. Until such data arrive, clinicians must balance efficacy signals against the distinct safety profiles of each BTK inhibitor.
In 2025, the United States recorded over four thousand new mantle cell lymphoma diagnoses.
